NewTimeSpace (newtimespace.com) News, on June 24, 2026, Mininglamp Technology (2718.HK) surged during morning trading. As of 10:06 AM, the company's share price was quoted at HK$240.600, up 7.89%.Relying on its multi-industry scenario knowledge bases, massive text corpora of real consumer intents, and extensive cross-platform engineering experience, Mininglamp Technology (2718.HK) has initiated integration practices with AI platforms such as WeChat and Tongyi Qianwen, comprehensively launching its Agent Ready solutions tailored for brand clients.
On June 23, Hong Kong stocks suffered a broad decline, triggering a sharp correction in the LLM and semiconductor sectors. MINIMAX plunged over 16% ahead of its impending lock-up expiration, while ZHIPU AI dropped 10%. On the industry front, both infrastructure development and commercial applications accelerated: Intel launched its "AI Home Brain" with domestic tech giants to propel the smart home ecosystem; Volcano Engine revealed Doubao's daily volume exceeded 180 trillion tokens alongside the release of Doubao 2.1 Pro; and DeepSeek established a dedicated "Harness" group to systematically build out its Agent infrastructure and product capabilities.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced on 23 June that the New Drug Application (NDA) for its CLDN18.2 ADC innovative drug Tecotabart Vedotin has been accepted by authorities for third-line and above gastric cancer treatment and has been granted priority review. The drug can precisely target CLDN18.2-positive tumors and exert bystander killing effect, with synergistic anti-tumor efficacy when combined with PD-1 antibody. Approximately 970,000 new gastric cancer cases are diagnosed globally each year, over one third of which occur in China, and CLDN18.2 represents a popular therapeutic target. A Phase III clinical trial of the ADC combined with PD-1 antibody for first-line treatment is also underway.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced on 23 June that its Class 1 innovative drug Pelecanam Spray (trade name: Puyike®) has obtained marketing approval from the National Medical Products Administration (NMPA), indicated for secondary wound infection resulting from burns and scalds. As a first-in-class ganan-class anti-infective agent globally, it delivers potent bactericidal efficacy against multiple drug-resistant bacteria. Key clinical trials demonstrated its therapeutic effect significantly outperforms the control group. Chia Tai Tianqing holds the exclusive commercialization rights for the product in China.
Leveraging its self-developed edge-side models Mano, Cito, and Mano-P, alongside the Cider inference framework, Mininglamp Technology(2718.HK) fully supports its strategic positioning in Agentic AI. Its new Agentic Services business generated over RMB 100 million in revenue during its inaugural year in 2025. Billed under an outcome-based delivery model of "token cost plus management fee," its four major application scenarios—performance advertising, brand advertising, content e-commerce, and micro-drama production—are already operating at scale.
NewTimeSpace (newtimespace.com) News: On June 23, 2026, the chip sector experienced a volatile retracement. HUA HONG GRACE (01347.HK) surged early in the morning session before pulling back. As of 13:20 PM, the company's share price was quoted at HK$163.700, down 0.55%.
NewTimeSpace (newtimespace.com) News: On June 23, 2026, the robot sector fluctuated and weakened. Midea Group (00300.HK) fluctuated downward, with the company's share price quoted at HK$81.450, down 1.45% as of 13:08 PM.
NewTimeSpace News: On June 23, 2026, BIDU-SW(09888.HK) traded choppily weaker in the morning session. As of 11:16, its share price stood at HK$106.10, representing a 2.39% decline. Apollo Go has expanded its footprint to 27 cities worldwide, recording more than 22 million cumulative ride-hailing orders. Its total autonomous driving mileage has exceeded 330 million kilometers, among which fully driverless mileage reaches 220 million kilometers.
NewTimeSpace (newtimespace.com) News, Choice data shows that as of June 22, 2026, Harfor CSI Artificial Industry ETF Feeder Fund-A (008020) and Harfor CSI Artificial Industry ETF Feeder Fund-C (008021) recorded gains of 1.73% respectively. Over the past three months, the two artificial intelligence-themed funds have jumped by 39.70% and 39.60% respectively.
NewTimeSpace News: China Medical System Holdings Limited (CMS, 00867.HK) announced that the New Drug Application for Silevimig Injection (GR1801, trade name: Jinsuxi®), an in-house developed Class 1 therapeutic biological product, has obtained marketing approval from the National Medical Products Administration (NMPA). It is indicated for passive immunization in adult patients exposed to rabies virus. This product is the world’s first bispecific antibody approved for rabies passive immunization.
On June 22, Hong Kong stocks finished lower, yet the LLM and domestic chip sectors erupted counter-trend, with MiniMax skyrocketing nearly 24%, while ZHIPU AI and Mininglamp surged over 14%. In global talent dynamics, Nobel laureate John Jumper announced his departure from Google DeepMind to join rival Anthropic. On the product front, Tencent initiated a limited beta for its native WeChat AI assistant "Xiaowei," powered by its proprietary WeLM and DeepSeek. Furthermore, data showed global LLM call volumes rose for the ninth consecutive week, with Chinese models sweeping the top four spots; DeepSeek captured an 18.5% global market share.
NewTimeSpace News: Hengrui Medicine announced on June 22 that the company has been notified by the European Medicines Agency (EMA) of the official validation and acceptance of its marketing authorization application for Relugolix Tablets for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) with high tumour burden.
NewTimeSpace News: Xinhua Pharmaceutical announced on June 22 that it has obtained the Clinical Trial Approval Notice for LXH-2103 Injection issued and approved by the National Medical Products Administration (NMPA), granting approval for clinical trials targeting moderate to severe postoperative pain.
NewTimeSpace News: Carsgen Therapeutics Holdings Limited (02171.HK) announced that the New Drug Application for Kailimei® (Satricabtagene Autoleucel Injection), an in-house developed Claudin18.2-targeted CAR-T cell therapy product, has been granted marketing approval by the National Medical Products Administration (NMPA). It is indicated for the treatment of advanced gastric/gastroesophageal junction adenocarcinoma that is Claudin18.2-positive, HER2-negative and has failed at least two lines of prior therapy. Kailimei® is the world’s first CAR-T cell therapy product approved for solid tumor treatment.
NewTimeSpace News: SSY Group Limited (02005.HK) announced that the Group has obtained manufacturing registration approvals from the National Medical Products Administration (NMPA) for two pharmaceutical products. Safinamide Mesylate Tablets (100mg & 50mg), classified as Class 4 chemical drugs and deemed to have passed consistency evaluation, make SSY the third domestic pharmaceutical firm to secure approval for this product. Meanwhile, Procaterol Hydrochloride Inhalation Solution (0.3ml:30μg), a Class 3 chemical drug, also received registration approval with deemed consistency evaluation clearance.
NewTimeSpace (newtimespace.com) News: On June 22, 2026, the chip sector experienced a volatile trading trend. ASMPT (00522.HK) opened lower and fluctuated, with the company's share price quoted at HK$202.400, down 3.07% as of 13:25 PM.
